Seelos Therapeutics, Inc. (Nasdaq: SEEL), a US-based clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced on Friday, that it is collaborating with the Sean M Healey & AMG Center for ALS (Amyotrophic Lateral Sclerosis).
The collaboration will involve an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.
As part of the EAP, Seelos is planning to initially enrol 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS along with its ongoing Phase II/III study on the HEALEY Platform. SLS-005, a low molecular weight disaccharide (0.342 kDa), is an investigational treatment and is not presently approved by any health authority for medicinal use.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference